Alvotech
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ALVO.IC | ALKS | NBIX | AMRX | BCRX | PCRX | |
|---|---|---|---|---|---|---|
| Market cap | 219.80B | 6.92B | 13.79B | 6.68B | 1.99B | 1.45B |
| P/E (TTM) | — | 108.5 | 19.9 | 39.1 | — | 103.8 |
| Forward P/E | — | 22.8 | 11.4 | 16.1 | 8.3 | 10.5 |
| Price/book | -1,147.1 | 3.8 | 3.7 | 186.2 | -4.4 | 2.2 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −38.27% | +33.05% | −3.98% | +87.30% | +20.97% | +57.86% |
| Today | −4.05% | +2.79% | −0.91% | −0.36% | −2.87% | +0.03% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 15 min.
Latest news
All ALVO.IC news ›Alvotech, Advanz Submit First Eylea 8 mg Biosimilar Bid
BioPharm International Alvotech and Advanz Pharma announced October 14, 2026, the submission of a European regulatory application for AVT29, a proposed biosimilar to Eylea 8 mg (aflibercept 114.3 mg/mL), which is marketed as Eylea HD in…
Alvotech files first known aflibercept 8 mg biosimilar with EMA
Ophthalmology Times Alvotech files first known aflibercept 8 mg biosimilar with EMA AVT29, filed as a line extension to Mynzepli, reaches EMA before its phase 3 comparative trial in DME reads out in mid-2027. Alvotech and Advanz Pharma…
Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg
Oct 14, 2026 4:30am EDT AVT29 submitted to the European Medicines Agency as a line extension to the existing marketing authorization for Mynzepli® (aflibercept 2 mg) High-dose aflibercept offers the potential to reduce treatment frequency…
Alvotech and Advanz Pharma Submit European Application for AVT29, High-Dose Biosimilar to Eylea 8 mg
Alvotech and Advanz Pharma submitted AVT29 as a proposed biosimilar to Eylea® 8 mg for retinal disease treatment in Europe. AVT29 is a proposed biosimilar to Eylea® 8 mg (aflibercept), aimed at treating retinal diseases. The high-dose…
Alvotech and Lotte Biologics Enter into Strategic Partnership for Biosimilars
Home / News / BioBlast® On 6 October 2026, Alvotech announced that it has entered into a strategic manufacturing partnership for biosimilars with Lotte Biologics. a contract development and manufacturing organisation (CDMO) that provides…
LOTTE Biologics and Alvotech Forge Long-Term Partnership to Expand Global Biosimilar Manufacturing Capacity
BioPharma APAC - LOTTE Biologics and Alvotech Forge Long-Term Partnership to Expand Global Biosimilar Manufacturing Capacity 13 October 2026 | Tuesday | News LOTTE Biologics and Alvotech Partnership Signing Ceremony Collaboration covers…
Alvotech (NASDAQ:ALVO) Stock Has Consensus Target Price of $8.50 According to Brokerages
Get Our Latest Report on Alvotech ALVO stock opened at $5.50 on Tuesday. The stock has a 50-day moving average price of $5.05 and a 200-day moving average price of $4.06. Alvotech has a 1-year low of $2.94 and a 1-year high of $9.05. The…
Alvotech Selects LOTTE Biologics' Syracuse Plant to Make Biosimilar Antibody Drug Substance
Alvotech turns to a CDMO's 40,000-liter Syracuse facility for biosimilar drug substance as it expands its manufacturing network. Alvotech has agreed to a long-term manufacturing partnership with LOTTE Biologics, under which the contract…
LOTTE Biologics and Alvotech announce US-based manufacturing agreement to increase global supply
The Manila Times LOTTE Biologics and Alvotech announce US-based manufacturing agreement to increase global supply Strategic long-term partnership with Alvotech to increase their global manufacturing capacity and support growth in demand…
Alvotech, LOTTE Biologics Forge Strategic Biosimilars Manufacturing Pact
Under the agreement, LOTTE Biologics will manufacture drug substance for multiple antibody biosimilar products at its Syracuse facility in New York for global supply, with the potential to further expand the collaboration over time. The…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
stocktitan.net5
-
manilatimes.net4
-
marketscreener.com4
-
biopharminternational.com3
-
quiverquant.com3
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 42 articles, not a forecast.